Conflict of interest: Nothing to report.
Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations†
Version of Record online: 27 OCT 2010
Copyright © 2010 Wiley-Liss, Inc.
American Journal of Hematology
Volume 85, Issue 12, pages 926–929, December 2010
How to Cite
Dvorakova, D., Racil, Z., Jeziskova, I., Palasek, I., Protivankova, M., Lengerova, M., Razga, F. and Mayer, J. (2010), Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. Am. J. Hematol., 85: 926–929. doi: 10.1002/ajh.21879
- Issue online: 23 NOV 2010
- Version of Record online: 27 OCT 2010
- Accepted manuscript online: 14 SEP 2010 12:00AM EST
- Manuscript Revised: 7 SEP 2010
- Manuscript Accepted: 7 SEP 2010
- Manuscript Received: 15 JUL 2010
- Unknown funding agency. Grant Number: MSM0021622430
- 1Acute myeloid leukaemia with recurrent genetic abnormalities. In: SwerdlowSH, CampoE, Lee HarrisN, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2008. pp 110–123., , , et al.
- 15Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 expression. Exp Hematol 2009; 37: 659–672., , , et al.